The Calamos S&P 500® Structured Alt Protection ETF® – February (CPSF) is slated to launch February 3, 2025, with an estimated upside cap range of 7.36%-7.75% over a one-year outcome period.
ADARx Pharmaceuticals, Inc. is a late-stage clinical biotechnology company dedicated to transforming cutting-edge science into next-generation RNA medicines across a wide range of therapeutic areas.
KBR Awarded Global Agreement by BP for Engineering, Procurement and Construction Management Services
HOUSTON, Jan. 13, 2025 /PRNewswire/ -- KBR (NYSE: KBR) announced today it has been awarded a global agreement by BP International Limited (bp) for engineering, procurement and construction management ...
Nutanix is a global leader in cloud software, offering organizations a single platform for running applications and managing data, anywhere. With Nutanix, companies can reduce complexity and simplify ...
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize ...
CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing regRNA-targeting antisense ...
By working with Fireblocks, IoTeX takes a significant step forward in making native IOTX and IoTeX-based assets accessible to ...
Enterprise performance management (EPM) tools, intended to minimize the problem of data being neither reliable nor accessible ...
As the latest addition to the Unstoppable ecosystem, Onchain joins more than 30 other prominent blockchain organizations, ...
CLEVELAND, Jan. 14, 2025 /PRNewswire/ -- The Riverside Company, a global private investment firm focused on the smaller end ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback